Brief: Oryzon Receives EMA Approval To Initiate A Phase II Study Of Iadademstat
24/02/2026 13:21
Feb 24 (Reuters) - Oryzon Genomics SA ORY.MC :
* ORYZON RECEIVES EUROPEAN MEDICINES AGENCY APPROVAL TO
INITIATE A
PHASE II STUDY OF IADADEMSTAT IN ESSENTIAL THROMBOCYTHEMIA
Source text: ID:nGNX3MPYPy
Further company coverage: ORY.MC
(((( Reuters.briefs@thomsonreuters.com ;));))
Recent news on ORYZON Genomics SA
See all newsBrief: Oryzon Gets New Patent Grants For Vafidemstat In Four Countries
Brief: Oryzon Gets EMA Approval To Start Phase II Study Of Vafidemstat For PMS Treatment
Spanish stocks - Factors to watch on Aug 31
Brief: Oryzon Gets U.S. Patent Allowance For Iadademstat And Gilteritinib Drug Combo Application
Spanish stocks - Factors to watch on July 28